ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 13 Sep 2024
Last Updated on 13 Sep 2024
A- A+
Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended dostarlimab for inclusion on the MOH List of Subsidised Drugs, when used in combination with carboplatin and paclitaxel, for treating mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost effectiveness of dostarlimab, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for dostarlimab are provided in the Annex.


Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer (Published 13 Sep 2024) PES Dostarlimab for treating primary advanced or recurrent endometrial cancer (Published 13 Sep 2024)